At a glance
ClinicalIndex Comparison RecordPhase 2Active· 8 enrolled
Drug / intervention
Talimogene Laherparepvec +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
In Brief
A Phase 2 clinical trial evaluating Talimogene Laherparepvec and Radiotherapy for Soft Tissue Sarcoma. Active but no longer recruiting, targeting 8 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 46 people will take part in this study conducted by investigators at the University of Iowa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2Active
20212022202320242025202620272028
Enrollment StartSep 2020
First PostedOct 2020
Primary CompletionFeb 2023
TodayJul 2026
Study CompletionFeb 2028
First PostedOct 22, 2020
Enrollment StartSep 10, 2020
Primary CompletionFeb 7, 2023
Study CompletionFeb 16, 2028
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.7 years ago
Interventions
Talimogene Laherparepvecdrug
Talimogene Laherparepvec
Radiotherapyradiation
Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.